LUTZ | ABEL advises in EUR 17 Million Series B round of financing for Temedica

LUTZ | ABEL advises in EUR 17 Million Series B round of financing for Temedica

LUTZ | ABEL advises in EUR 17 Million Series B round of financing for Temedica

The healthcare start-up Temedica GmbH from Germany announced to have completed a € 17 million Series B financing round.
close

The financing round was led by different MIG-Fonds, Santo Venture Capital, G+J Digital Ventures, Salvia and Bernd Wendeln as investors. LUTZ | ABEL advised on the transaction.

The German healthcare start-up Temedica GmbH, which is based in Munich and was founded by Gloria Seibert and Clemens Kofler, closed a € 17 million Series B financing round. MIG-Fonds, Santo Venture Capital and Salvia lead the round – existing shareholders like G+J Digital Ventures and Bernd Wendeln were additional investors.

Founded in 2016, the start-up develops digital companions (such as apps) to support patients in their healing process and to improve their medical care. Until today Temedica came up with the products pelvina (to strengthen the pelvic base), Mineo (to strengthen the back) as well as Waya (for a healthy nutrition and motion sequence). Further product developments are in the process of planning.

The LUTZ | ABEL team included the following attorneys: The partners Dr. Bernhard Noreisch (Munich) and Dr. Lorenz Jellinghaus (Hamburg) led the transaction. The team further consisted of Claudia Knuth (Employment Law, Hamburg), Andreas Kössel (Employment Law, Munich), Jan-Phillip Kunz (VC, Munich), Nina Sophie Osten (VC, Hamburg), Dr. Cornelius Renner (IT, Data Protection Law, Berlin), Ute Schenn (Commercial, Stuttgart), Dr. André Schmidt (IT, Data Protection Law, Hamburg).

The investors Santo Venture Capital and Salvia were represented by honert + partner (Sven Fritsche, Munich).